Reneuron Group: Milestones Expected As Pipeline Progresses
Edison | Jul 06, 2017 05:08AM ET
The highlight of FY17 was positive Phase II efficacy data from ReNeuron’s PISCES II clinical trial. As this and its other clinical programmes in ophthalmology and its earlier stage exosome platform progress, ReNeuron is entering a period of potentially significant milestones over the next 12 to 18 months. We maintain our valuation of £291m, adjusting for FY17 cash and rolling the model forward, which is offset by moving out the clinical timeline for the Phase III pivotal trial in stroke, now expected to start in early 2018 (vs H217).
Pivotal Phase III clinical trial planned early CY18
Reneuron Group (LON:RQE) received positive feedback from its end-of-Phase II meeting with the FDA for its Phase III stroke trial design. Alongside this it received a recommendation from the FDA to apply for a special protocol assessment (SPA) for the Phase III study. This is particularly encouraging as it indicates that, provided the endpoints are met, FDA approval should follow. ReNeuron has indicated that it now plans to apply for an SPA alongside a Regenerative Medicine Advanced Therapy (RMAT) designation (which would enable more interaction with the FDA during development and the possibility of accelerated review and approval) and an IND submission by the end of CY17 with the intention of starting a Phase III trial in the US in early 2018.
To read the entire report Please click on the pdf File Below:
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.